Please see also Carahealth Blood Sugar
Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. It affects one in five people, and prevalence increases with age. Some studies estimate the prevalence in the USA to be up to 25% of the population. Metabolic syndrome is also known as metabolic syndrome X, syndrome X, insulin resistance syndrome, Reaven's syndrome, and CHAOS (Australia).
Causes of metabolic syndrome
The exact mechanisms of the complex pathways of metabolic syndrome are not yet completely known. The pathophysiology is extremely complex and has been only partially elucidated. Most patients are older, obese, sedentary, and have a degree of insulin resistance. The most important factors in order are:
4. Sedentary lifestyle
There is debate regarding whether obesity or insulin resistance is the cause of the metabolic syndrome or if they are consequences of a more far-reaching metabolic derangement. A number of markers of systemic inflammation, including C-reactive protein, are often increased, as are fibrinogen, interleukin 6 (IL-6), Tumour necrosis factor-alpha (TNFα) and others. Interestingly all these inflammatory markers are associated with the pathogenesis of cancer. Some have pointed to oxidative stress due to a variety of causes including increased uric acid levels caused by dietary fructose.
Commonly there is development of visceral fat after which the adipocytes (fat cells) of the visceral fat increase plasma levels of TNFα and alter levels of a number of other substances (e.g., adiponectin, resistin, PAI-1). TNFα has been shown not only to cause the production of inflammatory cytokines, but possibly to trigger cell signalling by interaction with a TNFα receptor that may lead to insulin resistance. An experiment with rats that were fed a diet one-third of which was sucrose has been proposed as a model for the development of the metabolic syndrome. The sucrose first elevated blood levels of triglycerides, which induced visceral fat and ultimately resulted in insulin resistance . The progression from visceral fat to increased TNFα to insulin resistance has some parallels to human development of metabolic syndrome.
Risk factors for metabolic syndrome
Overweight and Obesity
Central obesity is a key feature of the syndrome, reflecting the fact that the syndrome's prevalence is driven by the strong relationship between waist circumference and increasing adiposity. However, despite the importance of obesity, patients who are normal weight may also be insulin-resistant and have the syndrome.
Physical inactivity is a predictor of CVD events and related mortality. Many components of the metabolic syndrome are associated with a sedentary lifestyle, including increased adipose tissue (predominantly central); reduced HDL cholesterol; and a trend toward increased triglycerides, blood pressure and glucose in the genetically susceptible. Compared with individuals who watched television or videos or used their computer <1 h daily, those who carried out these behaviors for >4 h daily have a twofold increased risk of the metabolic syndrome.
The metabolic syndrome affects 44% of the U.S. population older than age 50. A greater percentage of women older than age 50 have the syndrome than men. The age dependency of the syndrome's prevalence is seen in most populations around the world.
It is estimated that the large majority (~75%) of patients with type 2 diabetes or impaired glucose tolerance (IGT) have metabolic syndrome. The presence of the metabolic syndrome in these populations is associated with a higher prevalence of CVD than found in patients with type 2 diabetes or IGT without the syndrome. Hypoadiponectinemia (adiponectin is an adipose-specific protein with is putatively antiatherogenic and antiinflammatory effects), has been shown to increase insulin resistance and is considered to be a risk factor for developing metabolic syndrome.
Coronary Heart Disease
The approximate prevalence of the metabolic syndrome in patients with coronary heart disease (CHD) is 50%, with a prevalence of 37% in patients with premature coronary artery disease (age 45), particularly in women. With appropriate cardiac rehabilitation and changes in lifestyle (e.g., nutrition, physical activity, weight reduction, and, in some cases, Drugs), the prevalence of the syndrome can be reduced.
Signs and symptoms
Symptoms and features are:
- Fasting hyperglycemia - diabetes mellitus type 2 or impaired fasting glucose, impaired glucose tolerance, or insulin resistance;
- High blood pressure;
- Central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist;
- Decreased HDL cholesterol (the good cholesterol);
- Elevated triglycerides;
Associated diseases and signs are:
- hyperuricemia, fatty liver (especially in concurrent obesity) progressing to non-alcoholic fatty liver disease
- polycystic ovarian syndrome (in women)
- acanthosis nigricans( hyperpignentation of the skin due to insulin spill over)
The World Health Organization criteria (1999) require
- presence of diabetes mellitus,
- impaired glucose tolerance,
- impaired fasting glucose or insulin resistance,
AND two of the following:
* blood pressure: ≥ 140/90 mmHg
* dyslipidaemia: triglycerides (TG): ≥ 1.695 mmol/L and high-density lipoprotein cholesterol (HDL-C) ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female)
* central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), and/or body mass index > 30 kg/m2
* microalbuminuria: urinary albumin excretion ratio ≥ 20 mg/min or albumin:creatinine ratio ≥ 30 mg/g
The European Group for the Study of Insulin Resistance (1999) requires;
- insulin resistance defined as the top 25% of the fasting insulin values among non-diabetic individuals
AND two or more of the following:
* central obesity: waist circumference ≥ 94 cm (male), ≥ 80 cm (female)
* dyslipidaemia: TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L or treated for dyslipidaemia
* hypertension: blood pressure ≥ 140/90 mmHg or antihypertensive medication
* fasting plasma glucose ≥ 6.1 mmol/L
Various strategies have been proposed to prevent the development of metabolic syndrome. These include increased physical activity (such as walking 30 minutes every day), and a healthy, reduced calorie diet.
There are many studies that support the value of a healthy lifestyle as above. However, one study stated that these measures are effective in only a minority of people, primarily due to a lack of compliance with lifestyle and diet changes. The International Obesity Taskforce states that interventions on a sociopolitical level are required to reduce development of the metabolic syndrome in populations.
A 2007 study of 2,375 male subjects over 20 years suggested that daily intake of a pint of milk or equivalent dairy products more than halved the risk of metabolic syndrome.
Treatment of metabolic syndrome
The first line treatment is change of lifestyle (i.e., caloric restriction and physical activity). However, drug treatment is frequently required. Generally, the individual disorders that comprise the metabolic syndrome are treated separately.
Diuretics and ACE inhibitors may be used to treat hypertension.
Cholesterol drugs may be used to lower LDL cholesterol and triglyceride levels, if they are elevated, and to raise HDL levels if they are low.
Use of drugs that decrease insulin resistance, e.g., metformin and thiazolidinediones, is controversial; this treatment is not approved by the U.S. Food and Drug Administration.
A 2003 study indicated that cardiovascular exercise was therapeutic in approximately 31% of cases. The most probable benefit was to triglyceride levels, with 43% showing improvement; but fasting plasma glucose and insulin resistance of 91% of test subjects did not improve.
Many other studies have supported the value of increased physical activity and restricted caloric intake (exercise and diet) to treat metabolic syndrome.
Herbal Medicine and metabolic syndrome
For a full explanation of herbal medicines to treat blood sugar imbalace please see Carahealth Blood Sugar.
For a full naturopathic approach to treat metabolic syndrome please see also Natural Alternatives to the Antidiabetic Drug Avandia
1. MedlinePlus: Metabolic Syndrome
2. Ford ES, Giles WH, Dietz WH (2002). Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287(3):356-359. PMID 11790215
3. In his case studies poster presented at the Chronic Fatigue Syndrome Conference in Sydney, Australia (February 12-13, 1998), Dr Allen E. Gale, Consultant Physician (Allergy), identifies the acronym CHAOS as an abbreviation for Coronary artery disease, Hypertension, Atherosclerosis, Obesity, and Stroke.
4. Joslin EP. The prevention of diabetes mellitus. JAMA 1921;76:79-84.
5. Kylin E. [Studies of the hypertension-hyperglycemia-hyperuricemia syndrome] (German). Zentralbl Inn Med 1923;44: 105-27.
6. Vague J. La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité. Presse Med 1947;30:339-40.
7. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 1967;4:572-590. 8. Haller H. [Epidemiology and associated risk factors of hyperlipoproteinemia] (German). Z Gesamte Inn Med 1977;32(8):124-8. PMID 883354.
9. Singer P. [Diagnosis of primary hyperlipoproteinemias] (German). Z Gesamte Inn Med 1977;32(9):129-33. PMID 906591.
10. Phillips GB. Sex hormones, risk factors and cardiovascular disease. Am J Med 1978;65:7-11. PMID 356599.
11. Phillips GB. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci U S A 1977;74:1729-1733. PMID 193114.
12. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. PMID 3056758.
13. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, Patel JM, Johnson RJ (2006). "A causal role for uric acid in fructose-induced metabolic syndrome". Am J Phys Renal Phys 290 (3): F625-F631. doi:10.1152/ajprenal.00140.2005. PMID 16234313.
14. Hallfrisch J (1990). "Metabolic effects of dietary fructose". FASEB J 4 (9): 2652-2660. PMID 2189777.
15. Reiser S, Powell AS, Scholfield DJ, Panda P, Ellwood KC, Canary JJ (1989). "Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch". Am J Clin Nutr 49 (5): 832-839. PMID 2497634.
16. Fukuchi S, Hamaguchi K, Seike M, Himeno K, Sakata T, Yoshimatsu H. (2004). "Role of Fatty Acid Composition in the Development of Metabolic Disorders in Sucrose-Induced Obese Rats". Exp Biol Med 229 (6): 486-493. PMID 15169967. http://www.ebmonline.org/cgi/content/full/229/6/486.
17. ^ a b c d e f Fauci, Anthony S. (2008). Harrison's principles of internal medicine. McGraw-Hill Medical. ISBN 0-07-147692-X.
18. ^ Lara-Castro C, Fu Y, Chung BH, Garvey WT (June 2007). "Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease". Curr. Opin. Lipidol. 18 (3): 263-70. doi:10.1097/MOL.0b013e32814a645f. PMID 17495599. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00041433-200706000-00007.
19. Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH (January 2009). "Hypoadiponectinemia: a risk factor for metabolic syndrome". Acta Med Indones 41 (1): 20-4. doi:10.1267/science.040579197. PMID 19258676.
20. The IDF consensus worldwide definition of the metabolic syndrome. PDF
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. PMID 11368702.
22. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant D, for the Conference Participants. Definition of metabolic syndrome: report of the National, Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation. 2004;109:433-438.
23. American Heart Association's description of Syndrome X
24. Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K (March 2009). "High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population". J. Gastroenterol.. doi:10.1007/s00535-009-0002-5. PMID 19271113.
25. Lakka TA, Laaksonen DE (2007). "Physical activity in prevention and treatment of the metabolic syndrome". Applied physiology, nutrition, and metabolism = Physiologie appliquée, nutrition et métabolisme 32 (1): 76-88. doi:10.1139/h06-113. PMID 17332786.
26. Feldeisen SE, Tucker KL (2007). "Nutritional strategies in the prevention and treatment of metabolic syndrome". Appl Physiol Nutr Metab 32 (1): 46-60. doi:10.1139/h06-101. PMID 17332784.
27. Katzmaryk,, Peter T; Leon, Arthur S.; Wilmore, Jack H.; Skinner, James S.; Rao, D. C.; Rankinen, Tuomo; Bouchard, Claude (October 2003). "Targeting the Metabolic Syndrome with Exercise: Evidence from the HERITAGE Family Study.". Med. Sci. Sports Exerc 35 (10): 1703-1709. doi:10.1249/01.MSS.0000089337.73244.9B. http://www.ms-se.com/pt/re/msse/abstract.00005768-200310000-00013.htm. Retrieved on 2007-06-24.
28. James PT, Rigby N, Leach R (2004). "The obesity epidemic, metabolic syndrome and future prevention strategies". Eur J Cardiovasc Prev Rehabil 11 (1): 3-8. doi:10.1097/01.hjr.0000114707.27531.48. PMID 15167200.
29. Elwood, PC; Pickering JE, Fehily AM (2007). "Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study". J Epidemiol Community Health 61 (8): 695-698. doi:10.1136/jech.2006.053157. PMID 17630368. http://jech.bmj.com/cgi/content/abstract/61/8/695.
30. Snijder MB, van der Heijden AA, van Dam RM, et al (2007). "Is higher dairy consumption associated with lower body weight and fewer metabolic disturbances? The Hoorn Study". Am. J. Clin. Nutr. 85 (4): 989-95. PMID 17413097.
31. Richard Kahn (2008). "Metabolic syndrome-what is the clinical usefulness?". Lancet 371: 1892-1893. doi:10.1016/S0140-6736(08)60731-X.
32. Kahn R, Buse J, Ferrannini E, Stern M (2005). "The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes". Diabetes Care 28: 2289-2304. doi:10.2337/diacare.28.9.2289. PMID 16123508. Sources: adapted from Wikipedia
Carina is available to lecture for your group or institution on this subject.
Carina Harkin BHSc.Nat.BHSc.Hom.BHSc.Acu. is a practitioner of 11 years, complementary medicine lecturer of 4 years and mother of six in Galway, Ireland who practices what she teaches.
For an appointment call Carina directly on 083 34 66 333.
All products are available through www.carahealth.ie. Remember, we are here for a good time not a long time, enjoy your food life!
Carahealth Galway, Acupuncture, Naturopathy, Homeopathy, Herbal Medicine, Nutrition, Nutritional therapy, Flower essences, Iridology, Short Courses, Cosmetic Acupuncture